Le Lézard1d
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed ...
GlobalData on MSN12d
ViiV Healthcare and J&J’s adolescent HIV-1 combo gains EC authorisation
The European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus ...
MM&M4d
ViiV Healthcare wants to help patients, HCPs navigating HIV in video series
The Navigating HIV video series aims to role model what open and honest conversations between patients and HCPs can look like.
FiercePharma7d
How ViiV Healthcare plans to 'show up even better' in the fight against HIV in Black communities
Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV on Black communities. | Since 1999, Feb. 7 has marked National Black ...
Daily13d
European Commission authorises ViiV Healthcare Vocabria plus Rekambys for HIV treatment in adolescents
London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...
PharmiWeb15d
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
London, 31 January 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has ...
PharmiWeb15d
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...